FDA Approval for FoundationOne CDx in Pediatric Oncology
Foundation Medicine, Inc. has recently made significant strides in pediatric oncology with the approval of FoundationOne®CDx by the U.S. Food and Drug Administration (FDA). This test is designed as a companion diagnostic for Day One Biopharmaceuticals’ OJEMDA™, a new treatment option specifically aimed at pediatric patients suffering from relapsed or refractory pediatric low-grade glioma (pLGG). With this FDA endorsement, FoundationOne CDx is poised to play a critical role in identifying patients who could most benefit from this important therapy.
Understanding Pediatric Low-Grade Gliomas
Pediatric low-grade gliomas are among the most frequently diagnosed brain tumors in children, and up to 75 percent of these cases show BRAF alterations. Despite this high prevalence, there had previously been little in the way of FDA-approved treatment alternatives targeting BRAF fusions, which affect about 80 percent of BRAF altered cases. The advent of OJEMDA combines with the diagnostic capabilities of FoundationOne CDx to fill this gap, opening doors to novel treatment pathways for younger patients.
Comprehensive Genomic Profiling for Better Outcomes
Mia Levy, M.D., Ph.D., chief medical officer at Foundation Medicine, expressed pride in the partnership with Day One, emphasizing the importance of connecting families and healthcare providers with this new treatment option. The FoundationOne CDx diagnostic test innovatively detects both BRAF V600 mutations and fusions, enabling a comprehensive genomic overview that informs treatment decisions.
Addressing the Needs of Pediatric Patients
The introduction of OJEMDA and FoundationOne CDx couldn’t come at a more vital time. Children with relapsed or refractory pLGG historically faced severe side effects from aggressive treatments like chemotherapy or radiation. David Arons, president and CEO at the National Brain Tumor Society, underscored the relief this approval brings, stating that it expands treatment choices and enhances patient identification for potential therapies.
Foundation Medicine's Commitment to Advancing Cancer Care
Foundation Medicine has a proven track record in the field, having sequenced over 2,200 pediatric central nervous system tumors. The company stands out as the only entity offering FDA-approved tests for both tissue and blood-based comprehensive genomic profiling. Utilizing a tissue sample, the FoundationOne CDx test analyzes more than 300 cancer-related genes, placing Foundation Medicine at the forefront of companion diagnostic innovation.
About FoundationOne CDx
FoundationOne CDx is a leading-edge next-generation sequencing diagnostic tool designed to detect various genetic alterations across 324 genes. It evaluates substitutions, insertions, deletions, and genomic signatures like microsatellite instability and tumor mutational burden from formalin-fixed, paraffin-embedded tumor tissue. It is prescribed only to identify patients who may benefit from specific targeted treatments, allowing qualified healthcare professionals to make well-informed decisions aligned with contemporary oncology guidelines.
Frequently Asked Questions
What is FoundationOne CDx?
FoundationOne CDx is a next-generation sequencing diagnostic tool that detects genetic alterations in cancer, aiding in the identification of targeted therapies for patients.
How does the approval of FoundationOne CDx impact pediatric patients?
The approval allows healthcare providers to identify pediatric patients who may benefit from new targeted therapies, especially for low-grade gliomas with BRAF mutations.
What is the significance of BRAF mutations in pediatric low-grade gliomas?
BRAF alterations are prevalent in pediatric low-grade gliomas, influencing treatment decisions. The FoundationOne CDx test helps in detecting these mutations effectively.
Who can use FoundationOne CDx?
FoundationOne CDx is intended for use by qualified healthcare professionals in oncology to guide treatment decisions for patients with specific solid tumors.
What advantages does FoundationOne CDx offer over traditional testing?
This diagnostic test offers comprehensive genomic profiling, identifying more than 300 cancer-related genes, which facilitates personalized medicine and targeted therapy options.
